BoraLimMD

PubMed

• Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enha...
  Daisuke Morita, Amanda Rosewell Shaw, Greyson Biegert, Caroline Porter, Mae Woods
  Journal for Immunotherapy of Cancer. 2024-12-09
• Defining Breast Cryoablation Treatment Success: A Guide for the Curative and Palliative Treatment of Breast Cancer.
  Monica L Huang, Deanna L Lane, Lauren Q Chang Sen, Rosalind P Candelaria, Henry M Kuerer
  Academic Radiology. 2024-12-01
• Normal breast tissues harbour rare populations of aneuploid epithelial cells.
  Yiyun Lin, Junke Wang, Kaile Wang, Shanshan Bai, Aatish Thennavan
  Nature. 2024-11-20

Journal Articles

• Rates of Immune Cell Infiltration in Patients with Triple-Negative Breast Cancer by Molecular Subtype  
  Wendy A Woodward, Naoto T Ueno, Savitri Krishnamurthy, Bora Lim, PLoS One
• Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer  
  Michael C Stauder, Anthony Lucci, Wendy A Woodward, Bora Lim, Naoto T Ueno, ScienceDirect
• International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Con...  
  Ueno NT, Espinosa Fernandez JR, Cristofanilli M, Overmoyer B, Rea D, Berdichevski F, El-Shinawi M, Bellon J, Le-Petross HT, Lucci A, Babiera G, DeSnyder SM, Teshome M,..., J Cancer, 1/1/2018
• Genetic and pharmacological screens converge in identifying FLIP, BCL2 and IAP proteins as key regulators of sensitivity to the TRAIL-Inducing anticancer agent ONC201/...  
  Allen JE, Prabhu VV, Talekar M, van den Heuvel AP, Lim B, Dicker DT, Fritz JL, Beck A, El-Deiry WS, Cancer Res, 1/1/2015
• Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites  
  El-Deiry WS, Vijayvergia N, Xiu J, Scicchitano A, Lim B, Yee NS, Harvey HA, Gatalica Z, Reddy S, Cancer Biol Ther, 1/1/2015
• FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer  
  Lim B, Scicchitano A, Beachler C, Gusani N, Sarwani N, Yang Z, Staveley-O'Carroll K, Ashkenazi A, Portera C, El-Deiry WS, Cancer Biol Ther, 1/1/2013
• Join now to see all

Abstracts/Posters

• E6201, a novel MEK1 inhibitor, suppresses the metastatic capability of triple-negative breast cancer cells
  Lee J, Lim B, Choi K, Pearson T, Paradiso L, Myers T, Tripathy D, Ueno NT, AACR Annual Meeting, 1/1/2018
• Identification of molecular therapeutic targets that enhance the antitumor activity of neratinib in breast cancer cells
  Lim B, Lee J, Pearson T, Huey L, Hwang M, Choi K, Avogadri-Connors F, Cutler RE, Jr., Tripathy D, Ueno NT, AACR Annual Meeting, 1/1/2018
• Identification of biomarkers predictive of response to panitumumab combined with neoadjuvant chemotherapy for primary inflammatory breast cancer
  Wang W, Matsuda N, Lim B, Krishnamurthy S, Song J, Shen Y, Wu J, Hu J, Woodward WA, Reuben JM, Lucci A, Tripathy D, Valero V, Ueno NT, AACR Annual Meeting, 1/1/2018
• A phase II study using Talimogene Laherparepvec (T-VEC) as a single agent for inflammatory breast cnacer or non-inflammatory breast cnacer patients with inoperable loc...
  Willey JS, Marx AN, Lim B, Valero V, Ibrahim N, Reuben JM, Le-Petross HT, Whitman GJ, Krishnamurthy K, Woodward WA, Lucci A, Liu D, Ueno NT, SABCS, 1/1/2017
• Preclinical evaluation of imipridone ONC201 in triple negative breast cancer identifies predictive biomarkers and combinatorial opportunities
  Lim B, Lee J, Liu H, Pearson T, Coffer L, Tripathy D, Ueno NT, Cancer Res, 1/1/2017
• Oxidative phosphorylation as a target in triple negative breast cancer therapy
  Meric-Bernstam F, Evans K, Zheng X, Su X, Yuca E, Scott S, Akcakanat A, Ueno NT, Lim B, Litton J, Valero V, Symmans WF, Hortobagyi G, Perou C, Tripathy D, Draetta G, M..., Cancer Res, 1/1/2017
• Abstract CT062: NCT02456857: A phase II trial of liposomal doxorubicin, bevacizumab and everolimus (DAE) in patients with localized triple-negative breast cancer (TNBC...
  Damodaran S, Hess K, Rauch M, Astrada B, Santiago L, Litton J, Mittendorf M, Lim B, Ueno NT, Tripathy D, Thompson A, Gilcrease M, Yang W, Piwnica-Worms H, Symmans WF, ..., Cancer Res, 1/1/2017
• HER2 Somatic Mutation Analysis in Breast Cancer: Correlation with Clinicopathologic Features
  Ding Q, Chen H, Lim B, Damodaran S, Chen W, Tripathy D, Piha-Paul SA, Luthra R, Broaddus RR, Meric-Bernstam F, Sahin AA, Laboratory investigation proceedings, 1/1/2017
• Delineation of breast cancer based on circulating protein biomarker profile using the OLINK proteomics multiplexed proximity extension assay
  Jayachandran G, Cohen EN, Gao H, Alvarez RH, Valero V, Lim B, Woodward WA, Ueno NT, Reuben JM, Cancer Res, 1/1/2017
• A phase II trial of liposomal doxorubicin, bevacizumab and everolimus (DAE) in patients (pts) with localized triple-negative breast cancer (TNBC) with tumors predicted...
  Moulder S, Hess K, Rauch M, Astrada B, Litton J, Mittendorf E, Ueno NT, Tripathy D, Lim B, Piwnica-Worms H, Thompson A, Symmans WF, Cancer Res, 1/1/2017
• A phase IIB study of neoadjuvant ZT regimen (enzalutamide therapy in combination with weekly paclitaxel) for androgen receptor (AR)-positive triple-negative breast can...
  Fujii T, Lim B, Helgason T, Hess KR, Gilcrease MZ, Willey JS, Tripathy D, Litton JK, Moulder S, Krishnamurthy S, Yang W, Reuben JM, Symmans WF, Ueno NT, Cancer Res, 1/1/2017
• Phase IIB study of neoadjuvant panitumumab combined with carboplatin and paclitaxel (PaCT) for anthracycline-resistant triple-negative breast cancer (TNBC)
  Lim B, Helgason T, Hess KR, Piwnica-Worms H, Yang W, Adrada BE, Rauch GM, Gilcrease MZ, Symmans WF, Huo L, Mittendorf EA, Thompson A, Moulder S, Tripathy D, Ueno NT, Cancer Res, 1/1/2017
• TNBC Kinase Prioritization for Targeted Therapy after Chemotherapy Resistance
  Lim B, Park I, Lee J, Wang Y, Bollu L, Meric-Bernstam F, Tripathy D, Baggerly K, Brown PH, Ueno NT, Molecular Targets, 1/1/2017
• A randomized phase II study of neoadjuvant carboplatin/paclitaxel (CT) versus panitumumab/carboplatin/paclitaxel (PaCT) followed by anthracycline-containing regimen ...
  Willey JS, Parker CA, Marx AN, Lim B, Valero V, Le-Petross HT, Krishnamurthy K, Woodward WA, Lucci A, Wang X, Wood A, Sun H, Song J, Shen Y, Ueno NT, SABCS, 1/1/2017
• Classification of molecular subtypes of triple-negative breast cancer cell lines using two models
  Fernandez JR, Eckhardt BL, Lee J, Seitz RS, Hout DR, Ring BZ, Lim B, Ueno NT, SABCS, 1/1/2017
• Patterns of use and effectiveness of neoadjuvant pertuzumab-containing regimens in stage II-III HER2 neu positive breast cancer: a retrospective, single institutional ...
  Murthy RK, Raghavendra AS, Hess KR, Zhang HA, Lim B, Barcenas CH, Chavez-MacGregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson A, Valero V, Tripathy D, Ueno NT, SABCS, 1/1/2017
• Circulating protein biomarker profile for inflammatory breast cancer using a multiplexed proximity extension assay
  Cohen EN, Jayachandran G, Gao H, Tin S, Alvarez RH, Valero V, Lim B, Woodward WA, Ueno NT, Reuben JM, SABCS, 1/1/2017
• A single arm phase II study of adjuvant anti-PD1 (pembrolizumab) in combination with hormonal therapy in patients with hormone receptor (HR)-positive localized inflamm...
  Alexander A, Willey J, Sun H, Parker C, Marx A, Wood A, Reddy SM, Reuben JM, Bassett R, Le-Petross HT, Krishnamurthy S, Gong Y, Woodward WA, Valero V, Ueno NT, Lim B, SABCS, 1/1/2017
• Risk of needle-tracking seeding with serial ultrasound guided breast biopsies in triple negative breast cancers
  Yam C, Fornage BD, Santiago L, Candelaria RP, Adrada BE, Rauch GM, Hess KR, Litton JK, Piwnica-Worms H, Mittendorf EA, Ueno NT, Lim B, Murthy RK, Damodaran S, Helgason..., SABCS, 1/1/2017
• Androgen receptor (AR) positivity is associated with nodal disease in triple negative breast cancers
  Yam C, Huo L, Santiago L, CHess KR, Litton JK, Piwnica-Worms H, Mittendorf EA, Ueno NT, Lim B, Murthy RK, Damodaran S, Helgason T, Huo L, Thompson AM, andelaria RP, Ad..., SABCS, 1/1/2017
• Rates of immune inflitration in patients with triple-negative breast cancers by molecular subtype and in patients with inflammatory and non-inflammatory breast cancers
  Harano K, Wang Y, Lim B, Seitz RS, Morris SW, Bailey DB, Hout DR, Skelton RL, Ring BZ, Masuda H, Rao AUK, Woodward WA, Reuben JM, Ueno NT, SABCS Annual Meeting, 1/1/2016
• A Pilot Study: Radiogenomics of Inflammatory Breast Cancer
  Fujii T, Wang Y, Rao A, Lim B, Ueno NT, Le-Petross CH, 1/1/2016
• Phase 1b/2 safety and efficacy of TAK-228 (MLN0128), plus exemestane or fulvestrant in postmenopausal women with ER+/HER2- metastatic breast cancer
  Diamond JR, Borges VF, Kabos P, Krill-Jackson E, Graham R, Hoffman A, Lim B, Richards D, Salkeni MA, Wilks S, Patel C, Neuwirth R, Kneissi M, Zohren F, ESMO annual meeting, 1/1/2016
• Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER2-negative inflammatory breast cancer
  Matsuda N, Wang X, Willey J, Parker CA, James M, Brewster A, James RM, Stauder MC, Woodward W, Lucci A, Babiera G, DeSnyder SM, Alvarez RH, Lim B, Valero V, Tripathy D..., 1/1/2016
• New threshold of ER positivity in early-stage HER2-negative breast cancer
  Fujii T, Kogawa T, Dong W, Litton JK, Moulder SL, Tripathy D, Hunt K, Iwamoto T, Pusztai L, Shen Y, Lim B, Ueno NT, 1/1/2016
• Join now to see all

Lectures

• Novel combination of AR inhibitor and CDK4/6 inhibitor in non-HR positive (Triple Negative) breast cancers 
  Barcelona, Spain - 1/23/2018
• Clinical Updates, and New Initiatives 
  Houston, TX - 1/20/2018
• New Upcoming Therapeutics in TNBC 
  Houston, TX - 1/21/2017
• Targeting Apoptosis in Aggressive Breast Cancers 
  Osaka, Japan - 1/12/2017
• Local and Distant Recurrence in Breast Cancer 
  Houston, TX - 1/12/2017
• Updates on Cytotoxic Therapy for Metastatic Breast Cancer 
  Houston, TX - 1/12/2017
• Past, Present and Future of Breast Cancer 
  Houston, TX - 1/10/2017
• Latest Therapies for Breast 
  Houston, TX - 1/3/2017
• Inflammatory Breast Cancer Overview 
  Houston, TX - 1/30/2016
• Current Challenges in Treating Breast Cancer Patients with Mets to Brain 
  Jeju, Korea - 1/29/2016
• Past, Present and Future of TNBC 
  Seoul, South Korea - 1/1/2014
• Novel Biomarkers - CTC, TILs in Breast Cancer 
  Hershey, PA - 1/1/2014
• Novel combination strategy to target Triple Negative Breast Cancer 
  1/1/2013
• New Advances in Triple Negative Breast Cancer 
  Hershey, PA - 1/1/2013
• Feasibility of Applying Genomic Targeting in the Clinic 
  Hershey, PA - 1/1/2013
• Integrating Molecular Profiling into Day-to-Day Practice: Unexpected Response - a Sad, but Gratifying Case of Metastatic Breast Cancer 
  Valley Forge, PA - 1/1/2013
• Join now to see all